Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.42 |
| ▸ | WNT3A | P56704 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16418301 | 1.00 | MAPT (0.49) | MAPTCYP1A2CYP3A4CYP2D6MAPK1 | |
| SCHEMBL16418302 | 0.85 | MAPT (0.53) | MAPTCYP1A2CYP3A4CYP2D6MAPK1 | |
| SCHEMBL5479636 | 0.82 | CES2 (0.60) | MAPTCYP1A2CYP3A4CYP2D6MAPK1 | |
| SCHEMBL28533131 | 0.80 | CES2 (0.56) | MAPTCYP1A2CYP3A4CYP2D6MAPK1 | |
| SCHEMBL14267038 | 0.79 | CYP2C19 (0.47) | MAPTCYP1A2CYP3A4CYP2D6MAPK1 | |
| SCHEMBL8253633 | 0.79 | CYP2C19 (0.47) | MAPTCYP1A2CYP3A4CYP2D6MAPK1 | |
| SCHEMBL5263495 | 0.79 | ALDH1A1 (0.58) | MAPTCES2CES1MEN1KMT2A | |
| SCHEMBL995357 | 0.79 | ALDH1A1 (0.58) | MAPTCES2CES1MEN1KMT2A | |
| SCHEMBL995358 | 0.79 | ALDH1A1 (0.58) | MAPTCES2CES1MEN1KMT2A | |
| SCHEMBL15705183 | 0.78 | CYP1A2 (0.42) | MAPTCYP1A2CYP3A4CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352723-B1 | PESTICIDAL N-ARYL- OR N-HETEROARYL PYRAZOLE CARBOXAMIDE COMPOUNDS | BAYER IP GMBH (DE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
| EP-2352723-A2 | HALOGEN-SUBSTITUTED COMPOUNDS USED AS PESTICIDES | Bayer CropScience AG (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010051926-A2 | NEW HALOGEN-SUBSTITUTED BONDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301181-A1 | halogen-substituted compounds | L3MBTL4, QSOX1, L3MBTL3 | MAPT 4184/4885CYP1A2 80/4885CYP3A4 279/4885 |
| US-20150099766-A1 | Novel halogen-substituted compounds | L3MBTL4, PRDX4, PRDX1 | MAPT 4164/4885CYP1A2 174/4885CYP3A4 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.